Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and
Samuel Jalali1, Dakota Jenneman2, Ankita Tandon2
1Department of Internal and Hospital Medicine, Moffitt Cancer Center, Tampa, FL, U.S.A.; Samuel.Jalali@moffitt.org.
Background:
Thrombotic microangiopathy (TMA) is a clinical syndrome consisting of hemolytic anemia, thrombocytopenia, and presence of schistocytes on peripheral blood smear secondary to disorders of systemic microvascular thrombosis. Malignancy-associated TMA is a rare entity and shares clinical features with that of HUS and TTP usually seen in patients with metastatic cancer, tumor cell infiltration of the bone marrow and/or response to cancer-directed therapy.
Case Report:
We present a rare case of TMA secondary to breast cancer without evidence of bone marrow infiltration responsive to doxorubicin and cyclophosphamide treatment, after failed plasmapheresis with prednisone and later, eculizumab.
Conclusion:
Despite being a rare manifestation of metastatic carcinoma, early identification and treatment are essential to improving survival.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules


